Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of GMRx2 (a Single Pill Combination Containing Telmisartan/Amlodipine/Indapamide) Compared to Placebo for the Treatment of Hypertension

Next Previous
X
Search
Trial Profile

Efficacy and Safety of GMRx2 (a Single Pill Combination Containing Telmisartan/Amlodipine/Indapamide) Compared to Placebo for the Treatment of Hypertension

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amlodipine/indapamide/telmisartan-George Medicines (Primary)
  • Indications Hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms GMRx2_PCT
  • Sponsors George Medicines

    • Most Recent Events

    • 13 Dec 2023 Status changed from recruiting to completed.
    • 12 Jul 2023 According to a George Medicines media release, this clinical trial now actively recruiting patients further in Europe and into Africa and South Asia, in collaboration with the Imperial Clinical Trials Unit (ICTU) at Imperial College London and RemediumOne in Sri Lanka.
    • 12 Jul 2023 According to a George Medicines media release, company recently expanded this phase 3 trial, into the UK, Nigeria and Sri Lanka, in collaboration with global clinical research organization George Clinical.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top